These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 23324505)

  • 1. High-dose oral medroxyprogesterone for inappropriate hypersexuality in elderly men with dementia: a case series.
    Cross BS; DeYoung GR; Furmaga KM
    Ann Pharmacother; 2013 Jan; 47(1):e1. PubMed ID: 23324505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medroxyprogesterone acetate (MPA) treatment of sexual acting out in men suffering from dementia.
    Cooper AJ
    J Clin Psychiatry; 1987 Sep; 48(9):368-70. PubMed ID: 2957362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
    Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
    Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug treatment of paraphilic and nonparaphilic sexual disorders.
    Guay DR
    Clin Ther; 2009 Jan; 31(1):1-31. PubMed ID: 19243704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
    Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
    Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose oral medroxyprogesterone acetate in the management of the paraphilias.
    Gottesman HG; Schubert DS
    J Clin Psychiatry; 1993 May; 54(5):182-8. PubMed ID: 8509348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
    Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
    Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
    Klaassen DJ; Rapp EF; Hirte WE
    Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy.
    Prior JC; Nielsen JD; Hitchcock CL; Williams LA; Vigna YM; Dean CB
    Clin Sci (Lond); 2007 May; 112(10):517-25. PubMed ID: 17419685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
    Nomura Y; Tashiro H; Hisamatsu K; Toi M
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medroxyprogesterone and paraphiles: do testosterone levels matter?
    Kravitz HM; Haywood TW; Kelly J; Liles S; Cavanaugh JL
    Bull Am Acad Psychiatry Law; 1996; 24(1):73-83. PubMed ID: 8891323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
    Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
    Kohen I; Preval H; Southard R; Francis A
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.
    Robustelli della Cuna G; Zanon P; Pavesi L; Preti P; Prada GA; Decensi A
    Chemioterapia; 1986 Jun; 5(3):164-72. PubMed ID: 2941173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medroxyprogesterone acetate acutely facilitates and sequentially inhibits sexual behavior in female rats.
    Pazol K; Northcutt KV; Wilson ME; Wallen K
    Horm Behav; 2006 Jan; 49(1):105-13. PubMed ID: 16095597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
    Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
    Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.
    Braunstein GD; Sundwall DA; Katz M; Shifren JL; Buster JE; Simon JA; Bachman G; Aguirre OA; Lucas JD; Rodenberg C; Buch A; Watts NB
    Arch Intern Med; 2005 Jul; 165(14):1582-9. PubMed ID: 16043675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.